Načítá se...

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Leukemia
Hlavní autoři:	Lancet, JE, Ravandi, F, Ricklis, RM, Cripe, LD, Kantarjian, HM, Giles, FJ, List, AF, Chen, T, Allen, RS, Fox, JA, Michelson, GC, Karp, JE
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	2011
Témata:	Article
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4576993/ https://ncbi.nlm.nih.gov/pubmed/21760592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.157
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Podobné jednotky